Use of pegylated interferon in hypereosinophilic syndrome

Leukemia Research

Volumn 36, Issue 2, 2012, Pages 192-197

  Butterfield, Joseph H ^a   Weiler, Catherine R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Eosinophilia; Hypereosinophilic syndrome; Immunoglobulins; Interferon; Methoxy polyethylene glycol

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AZATHIOPRINE; CYCLOSPORIN; FLUORODEOXYGLUCOSE F 18; FLUTICASONE PROPIONATE PLUS SALMETEROL; HYDROCORTISONE SODIUM SUCCINATE; HYDROXYUREA; METHYLPREDNISOLONE SODIUM SUCCINATE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; RADIOACTIVE IODINE;

ADULT; AGED; ANEMIA; ANGIONEUROTIC EDEMA; ANXIETY; APHASIA; ARTICLE; ASTHMA; BONE MARROW BIOPSY; BRAIN INFARCTION; BRONCHIECTASIS; BRONCHITIS; CHROMOSOME 20; CHROMOSOME REARRANGEMENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONFUSION; CORONARY ARTERY ATHEROSCLEROSIS; DEHYDRATION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELUTING STENT; DRUG INTERMITTENT THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHIL COUNT; EOSINOPHILIC BRONCHITIS; FATIGUE; FEMALE; FEVER; GRAVES DISEASE; HAIR LOSS; HEART INFARCTION; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ODYNOPHAGIA; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; SINUSITIS; SKIN BIOPSY; SPLENOMEGALY; TREMOR; URTICARIA; VISUAL DISORDER; WEAKNESS; WEIGHT REDUCTION; WELLS SYNDROME;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84855188876     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.09.026     Document Type: Article

References (40)

1. Murphy P.T., Fennelly D.F., Stuart M., O'Donnell J.R. Alfa-interferon in a case of hypereosinophilic syndrome. Br J Haematol 1990, 75(August (4)):619-620.
2. Zielinski R.M., Lawrence W.D. Interferon-alpha for the hypereosinophilic syndrome. Ann Intern Med 1990, 113(November (9)):716-718.
3. Fruehauf S., Fiehn C., Haas R., Doehner H., Hunstein W. Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy. Acta Haematol 1993, 89(2):91-93.
4. Ceretelli S., Capochiani E., Petrini M. Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol 1998, 77(October (4)):161-164.
5. Yoon T.Y., Ahn G.B., Chang S.H. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J Dermatol 2000, 27(February (2)):110-115.
6. Yamada O., Kitahara K., Imamura K., Ozasa H., Okada M., Mizoguchi H. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol 1998, 58(June (2)):137-141.
7. Kobayashi M., Katayama T., Ochiai S., Yoshida M., Kaito K., Masuoka H., et al. Interferon-alpha therapy in the myeloproliferative variants of hypereosinophilic syndrome. Rinsho Ketsueki 1993, 34(March (3)):367-372. [in Japanese].
8. Bockenstedt P.L., Santinga J.T., Bolling S.F. Alpha-interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol 1994, 45(March (3)):248-251.
9. Baratta L., Afeltra A., Delfino M., De Castro S., Giorgino F., Rossi-Fanelli F. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy: case report and literature review. Angiology 2002, 53(July-August (4)):465-470.
10. Hansen P.B., Johnsen H.E., Hippe E. Hypereosinophilic syndrome treated with alpha-interferon and granulocyte colony-stimulating factor but complicated by nephrotoxicity. Am J Hematol 1993, 43(May (1)):66-68.
11. Butterfield J.H., Gleich G.J. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994, 121(November (9)):648-653.
12. Busch F.W., Schmidt H., Steinke B. Alpha-interferon for the hypereosinophilic syndrome. Ann Intern Med 1991, 114(February (4)):338-339.
13. Quiquandon I., Claisse J.F., Capiod J.C., Delobel J., Prin L. Alpha-interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission. Blood 1995, 85(April (8)):2284-2285.
14. Luciano L., Catalano L., Sarrantonio C., Guerriero A., Califano C., Rotoli B. AlphaIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica 1999, 84(July (7)):651-653.
15. Schoffski P., Ganser A., Pascheberg U., Busche G., Gaede B., Hertenstein B. Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. Ann Hematol 2000, 79(February (2)):95-98.
16. Acaba L., Mangual A., Velez Garcia E. Excellent response to interferon therapy in a patient with hypereosinophilic syndrome and elevated serum immunoglobulin E levels. Bol Asoc Med P R 2000, 92(April-August (4-8)):59-62.
17. DeYampert N.M., Beck L.A. Eosinophilia and multiple erythematous indurated plaques: idiopathic hypereosinophilic syndrome (IHS). Arch Dermatol 1997, 133(December (12)):1581-1584.
18. Aldebert D., Lamkhioued B., Desaint C., Gounni A.S., Goldman M., Capron A., et al. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood 1996, 87(March (6)):2354-2360.
19. Kioke T., Nakamura Y., Enokihara H. Interferon-α inhibits interleukin-5 and granulocyte-macrophage colony formation from bone marrow progenitor cells. Dokkyo J Med Sci 1998, 25:45-52.
20. Desreumaux P., Janin A., Dubucquoi S., Copin M.C., Torpier G., Capron A., et al. Synthesis of interleukin-5 by activated eosinophils in patients with eosinophilic heart diseases. Blood 1993, 82(October (5)):1553-1560.
21. Krishnaswamy G., Smith J.K., Srikanth S., Chi D.S., Kalbfleisch J.H., Huang S.K. Lymphoblastoid interferon-alpha inhibits T cell proliferation and expression of eosinophil-activating cytokines. J Interferon Cytokine Res 1996, 16(October (10)):819-827.
22. Enokihara H., Nakamura Y., Nagashima S., Furusawa S., Shishido H. Regulation of interleukin-5 production by interleukin-4, interferon-alpha, transforming growth factor-beta and interleukin-6. Int Arch Allergy Immunol 1994, 104(Suppl 1(1)):44-45.
23. Krishnaswamy G., Hall K., Youngberg G., Hossler F., Johnson D., Block W.A., et al. Regulation of eosinophil-active cytokine production from human cord blood-derived mast cells. J Interferon Cytokine Res 2002, 22(March (3)):379-388.
24. Ochiai K., Iwamoto I., Takahashi H., Yoshida S., Tomioka H., Yoshida S. Effect of IL-4 and interferon-gamma (IFN-gamma) on IL-3- and IL-5-induced eosinophil differentiation from human cord blood mononuclear cells. Clin Exp Immunol 1995, 99(January (1)):124-128.
25. Nakajima T., Yamashita N., Matsui H., Suzuki N., Kaneoka H., Mizushima Y., et al. Induction of differentiation into monocyte/macrophage cell lineage of a human eosinophilic leukaemia cell line EoL-1 by simultaneous stimulation with tumour necrosis factor-alpha and interferon-gamma. Br J Haematol 1995, 89(February (2)):258-265.
26. Morita M., Lamkhioued B., Soussi Gounni A., Aldebert D., Delaporte E., Capron A., et al. Induction by interferons of human eosinophil apoptosis and regulation by interleukin-3, granulocyte/macrophage-colony stimulating factor and interleukin-5. Eur Cytokine Netw 1996, 7(December (4)):725-732.
27. Quintas-Cardama A., Kantarjian H.M., Giles F., Verstovsek S. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost 2006, 32(June (4 Pt 2)):409-416.
28. Husa P., Slesinger P., Stroblova H., Svobodník A., Husova L. Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics. Klin Mikrobiol Infekc Lek 2008, 14(April (2)):67-73. [in Czech].
29. Kiladjian J.J., Cassinat B., Chevret S., Turlure P., Cambier N., Roussel M., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112(October (8)):3065-3072. Epub 2008 July 23.
30. Grace M., Youngster S., Gitlin G., Sydor W., Xie L., Westreich L., et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res 2001, 21(December (12)):1103-1115.
31. Jabbour E., Kantarjian H., Cortes J., Thomas D., Garcia-Manero G., Ferrajoli A., et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007, 110(November (9)):2012-2018.
32. Butterfield J.H. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol Allergy Clin North Am 2007, 27(August (3)):493-518.
33. Bukowski R.M., Tendler C., Cutler D., Rose E., Laughlin M.M., Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002, 95(July (2)):389-396.
34. Lindsay K.L., Trepo C., Heintges T., Shiffman M.L., Gordon S.C., Hoefs J.C., et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001, 34(August (2)):395-403.
35. Simon H.U., Rothenberg M.E., Bochner B.S., Weller P.F., Wardlaw A.J., Wechsler M.E., et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126(July (1)):45-49.
36. Vilcek J., Feldmann M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 2004, 25(April (4)):201-209.
37. Glue P., Fang J.W., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000, 68(November (5)):556-567.
38. Physicians' desk reference 2008 2007, Thomson PDR, Montvale (NY), p. 2994-3001. 62nd ed.
39. Brigaudeau C., Liozon E., Bernard P., Trimoreau F., Bordessoule D., Praloran V. Deletion of chromosome 20q associated with hypereosinophilic syndrome: a report of two cases. Cancer Genet Cytogenet 1996, 87(March (1)):82-84.
40. Huh J., Tiu R.V., Gondek L.P., O'Keefe C.L., Jasek M., Makishima H., et al. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer 2010, 49(April (4)):390-399.